When Might Kratom Testing Be Considered?
After learning what kratom is and why standard drug panels generally don't detect it, the final question is practical: When might an organization consider testing for it?
There isn't a one-size-fits-all answer.
For some treatment and recovery programs, kratom may be relevant because participants could be using kratom products during recovery or as an alternative to other substances. Understanding that use may be important to the program's monitoring approach and individual treatment goals.
Certain employers may also encounter questions about kratom, particularly when reviewing their drug-free workplace policies or determining which substances are relevant to safety-sensitive positions. However, organizations should consider applicable state and local laws, written policies, and professional guidance before adding any substance to a testing program.
The type of test matters, too. As we covered in Part 2, simply moving from a 5-panel to a larger drug panel doesn't guarantee kratom detection. Organizations specifically seeking kratom screening should verify which analytes the test detects, such as mitragynine or 7-hydroxymitragynine (7-OH).
Ultimately, adding another substance isn't about creating the biggest possible panel. It's about determining what information your organization actually needs and selecting testing options that support those objectives.
Fact Friday takeaway:
Kratom testing may be appropriate for certain programs, but the decision should be driven by testing objectives, policies, applicable requirements, and the specific compounds a test is designed to detect.
Using a credible resource for drug screening supplies helps support consistency and reliability across your program.
